Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) announced that the National Medical Products Administration (NMPA) has granted market approval for its Toumai single-arm single-hole laparoscopic surgical robot. The device is designed to perform minimally invasive surgeries through a single incision, offering clinical benefits such as reduced scarring and faster recovery.
Product Highlights
The Toumai robot features a proprietary single-arm structure with a snake-like design, enabling seven degrees of freedom in narrow spaces. This design allows for greater precision compared to traditional multi-arm robots, facilitating complex maneuvers in confined areas. The single-hole approach minimizes surgical trauma, resulting in smaller wounds, less postoperative pain, and improved cosmetic outcomes for patients.
Clinical Value
The NMPA approval positions Toumai as a next-generation surgical tool, addressing unmet needs in laparoscopic procedures. MicroPort MedBot plans to leverage the device’s advantages to expand its presence in the minimally invasive surgery market, targeting hospitals seeking advanced robotic platforms.-Fineline Info & Tech
